Review Article

International Journal of Indigenous Herbs and Drugs
Content Available at www.saapjournals.org ISSN: 2456-7345



FUTURE PERSPECTIVES OF PHARMACOGENOMICS IN PERSONALIZED MEDICINE

RUDRA SANDHYA*, DEVARAKONDA KEERTHI, B. GAYATHRI, CHANDU BABU RAO

Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

ARTICLE INFO

Article History
Received on: 24-04-2026
Revised on: 15-05-2026
Accepted on: 01-06-2026

***CORRESPONDING AUTHOR**
Rudra Sandhya

ABSTRACT

By making patient-specific medication therapy possible, developments in pharmacogenomics and artificial intelligence (AI) are revolutionizing personalized medicine. Pharmacogenomics addresses interindividual variability in treatment outcomes by examining the ways in which genetic variants impact medication metabolism, effectiveness, and safety. Genetic variations in drug-metabolizing enzymes, transporters, and targets are important factors that influence both therapeutic response and adverse drug reactions, according to recent studies. However, conventional analytical methods face considerable difficulties due to the size and complexity of genetic and clinical data. AI has become a potent tool for analysing high-dimensional pharmacogenomic datasets, identifying gene–drug interactions, and more accurately predicting medication responses. This is especially true of machine learning and deep learning techniques.

Keywords: -Pharmacogenomics, Precision, Drug Response Prediction, Variability, Genetic Variability Healthcare.

1. INTRODUCTION

Definition of Pharmacogenomics and Personalised Medicine: Pharmacogenomics is the study of how a person's genetic composition affects how they react to drugs. In order to provide individualised treatment plans based on each patient's unique genetic profile, this discipline focuses on finding genetic differences that impact drug metabolism, efficacy, and potential side effects [1]. When a gene mutation is connected to a patient's specific drug reaction, treatment decisions, including adjusting the dosage or choosing an alternative prescription, may be based on genetics. Researchers find genetic loci associated with established medication reactions and then test individuals whose response to the drug is unknown to evaluate gene variants influencing an individual's response, much like they do when evaluating gene variations connected to disease. Two modern methods that are only now being applied clinically for drug development are whole-genome single nucleotide polymorphism (SNP) profiling and multi-gene analysis [1, 2]. In 1909, Archibald Garrod predicted that "every active drug is a poison, when taken in large enough doses, and in some subjects, a dose which is innocuous to the majority of people has toxic effects, whereas others show exceptional tolerance to the drug." Garrod also suggested that some diseases have a genetic basis due to inborn errors in metabolism. Arthur L. Fox's 1932 discovery that some people cannot taste the bitter taste of phenylthiocarbamide, which is found in broccoli, led to the demonstration of genetic factors in response to xenobiotics [3].

2. PRINCIPLE OF GENETICS AND GENOMICS

Complexity of Genes and the Genome-Integration of Diverse Large Datasets: In order to create predictive biomarker panels of drug response, pharmacogenetics initially concentrated on genetic variants that alter the protein sequence, such as non-synonymous single nucleotide polymorphisms (unsnaps). Whole exome sequencing can easily identify unsnaps, which are modifications in the DNA coding sequence (Silgado-Guzman et al., 2022). However, genome-wide association studies (GWAS) have shown that the majority of variants linked to clinical phenotypes are either synonymous single nucleotides (SNPs) in coding regions that do not change the protein sequence (e.g., rs3435 in ABCB1, encoding MDR1, destabilizing the RNA) or reside in un transcribed domains, noncoding RNAs, and noncoding regions of protein genes (Wang et al., 2005) [4].

3. IMPORTANCE OF PHARMACOGENOMICS IN PRECISION MEDICINE

Pharmacogenomics has become a key component of precision medicine in recent years, a science that aims to tailor treatment plans to each patient's particular biological composition. Precision medicine uses genetic information to predict treatment responses, reduce side reactions, and improve drug efficacy, in contrast to the

conventional "one-size-fits-all" approach. The study of pharmacogenomics Investigating these subjects is essential to this strategy because it offers insights on gene-drug interactions that enable doctors to choose drugs that are not only safe and efficient for every person. For example, finding genetic variations in the CYP450 family of enzymes can greatly increase the accuracy of dosing for drugs like anticoagulants and antidepressants that have limited therapeutic windows. [5]

4. PHARMACOGENOMIC TESTING APPROACHES

Pharmacogenomic testing is essential for converting genetic data into useful clinical insights that support customized treatment strategies. Pharmacogenomic testing uses a variety of approaches and procedures, each with unique advantages and disadvantages. Pharmacogenomic testing frequently uses genotyping, which entails the examination of particular genetic variations. The identification of genetic variants linked to drug response is made easier by methods like next-generation sequencing (NGS), DNA microarrays, and polymerase chain reaction (PCR). For targeted genotyping, PCR-based techniques with high specificity and sensitivity include allele-specific PCR and real-time PCR. While NGS enables thorough study of the entire genome or certain gene areas, DNA microarrays allow testing for many genetic variants at the same time [6]. Pharmacogenomic testing has limitations and difficulties when used in standard clinical practice. Interpreting genetic variations and their clinical significance is a major difficulty. . Although numerous variations have been connected to drug responsiveness, not all of them have established treatment guidelines or been conclusively linked to clinical outcomes. Interpretation is further complicated by the existence of several genetic variations and their possible interactions. For reliable and consistent results across various labs and clinical contexts, standardization of pharmacogenomic testing platforms, variant classification, and reporting protocols is essential. The affordability of pharmacogenomic testing is another drawback. Broad adoption may be hampered by the costs of genetic testing, especially when using NGS-based techniques. However, pharmacogenomic testing is becoming more economically viable as sequencing technology costs continue to drop and specialized genotyping panels are developed. Another difficulty is incorporating pharmacogenomic testing into clinical practice. To comprehend the ramifications of pharmacogenomic test results, interpret them in light of unique patient features, and use the data to determine treatment choices, healthcare professionals need education and training. Additionally, the smooth integration of pharmacogenomic data into the clinical workflow depends on the development of clinical decision support systems and electronic health record (EHR) integration. To overcome these obstacles and promote broad acceptance, researchers, physicians, laboratory specialists, and legislators must work together to realize the full potential of pharmacogenomic testing].Attempts are being made to incorporate pharmacogenomic testing into standard clinical care in spite of these obstacles. Pharmacogenomic testing programs have been implemented in a number of institutions and healthcare systems, and groups like the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have created guidelines and recommendations for particular drug-gene pairs. The clinical efficacy and cost-effectiveness of pharmacogenomic testing are being investigated by collaborative research programs, which are producing useful data to direct its incorporation into standard treatment [7].

5. ROLE OF PHARMACOGENOMIC IN ADVERSE DRUG REACTION

Drug reactions may result in undesirable side effects. The term "adverse drug reactions" (ADRs) is favored when these can be directly linked to a specific medication. Genetic variation greatly raises the risk of acquiring ADRs, which are major causes of morbidity and mortality. In their most basic forms, adverse medication reactions fall into either Type A (pharmacological) or Type B (idiosyncratic) categories. Pharmacological reactions are caused by an adverse reaction to the known mechanism of action, have a dose-dependent occurrence, and may be comprehended and even anticipated given the drug's identified targets. CYP2D6 and opiate-induced respiratory depression or CYP2C9 and bleeding on warfarin treatment are examples of highly penetrant risk alleles within drug-metabolizing enzyme genes that demonstrate how genetic variation contributing to pharmacokinetic mechanisms may be significant for these adverse medication reactions. On the other hand, idiosyncratic adverse drug reactions (ADRs) are less common and not predicted by the drug's known pharmacological profile, yet they can be lethal and cause serious organ damage. Many of these ADRs have been associated with immunological processes, and most guidelines associate them with variations in immune response genes, especially those related to the HLA system. These results show that developing ADR prediction systems to improve patient safety and resource efficiency is feasible. Over the course of five years, at least 65% of primary care patients are thought to be exposed to drugs with pharmacogenomic indications. In these cases, genomic information may be utilized to avoid or reduce adverse drug reactions. Among the drugs prescribed for regular treatment, these are rather overrepresented. The utility of this information is currently being examined at scale, with the potential to standardize pharmacogenomic variance being recorded on routine health records and incorporated to warning and monitoring systems to help with prescribing decisions [8].

6. PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT

Drug development and discovery now heavily relies on genomics, which helps bring new medications to market. Integration of the proteome and metabolome, transcriptomes of impacted tissues, and genetic sequence

aids in the identification of legitimate therapeutic targets. For instance, genetics had shown that a lack of PCSK9 protected against cardiovascular disorders by lowering cholesterol levels, which led to successful treatments using PCSK9 antibodies or RNA blockers. As mentioned, Oncogenic mutations are the subject of targeted anticancer medication discovery. However, the majority of prevalent conditions, including diabetes, heart disease, and mental illnesses, have a polygenic basis. Although the intricacy of gene networks has slowed research, many common illnesses might theoretically be divided into subtypes based on unique pathophysiology and genetics. However, biomarkers can be used to determine which patient subgroups are most benefiting from a particular medication or who are more likely to experience adverse drug reactions. Understanding how genes behave, their interactions, how they operate in biological processes, and how they vary among populations will all be beneficial to drug discovery. Calculating variations in gene expression from Potential targets for therapeutic development are normal tissues via the beginning of disease in uncommon populations [9]. The current focus on target validation will eventually need to give way to goal planning that is genetics-focused. Limiting the testing of too many hypotheses that can eventually be proven is necessary when using genetically supported goal determination techniques. Reducing attrition and increasing a product's return on investment are indicators of discovery success. One of the biggest problems facing modern clinical practice, medication development, and drug regulation is individual diversity in treatment efficacy and safety [10].

7. METHODOLOGICAL INNOVATIONS IN AI-ENHANCED PHARMACOGENOMIC STUDIES

A. A variety of techniques, such as deep learning, machine learning, and big data analytics, are used to leverage AI for pharmacogenomic research. By making it possible to analyze vast volumes of data and extract valuable information from biomedical genetic datasets, these approaches have the potential to completely transform pharmacogenomics and personalized medicine. This section examines some of the most important approaches and difficulties [11].

B. Machine learning and deep learning

There have been encouraging advancements in the application of deep learning and machine learning to pharmacogenomic research. By combining pharmacokinetics and genomes, these methods make it possible to analyze vast amounts of data, which makes them ideal for drug discovery. One benefit of deep learning, a subset of machine learning, is representation learning, which does away with the need for feature extraction and has raised the bar for many machine learning applications, such as drug discovery and genomics. Beyond conventional single-variable and multivariable statistical techniques, the application of AI approaches such as machine learning, deep learning, and probabilistic graphs offers pharmacogenomics a timely synergy [12].

A. Big data analytics

Big data analytics has been found to be a transformative method in pharmacogenomics research, allowing for the effective management and analysis of the significant amount of data produced in this area. Pharmacogenomics' massive data inflow poses a problem because conventional analysis techniques, including statistical correlation or visual analysis, are insufficient to manage such massive datasets. However, by enabling the effective administration of the data as well as the autonomous identification and analysis of patterns within the data, the application of AI and machine learning techniques, particularly big data analytics, mitigates this problem. These methods can be used to enhance patient care and medication development since they offer the capacity to forecast the pharmacological characteristics of therapeutic targets, which is particularly advantageous in clinical settings.

Big data analytics and AI have the potential to produce useful insights from the patterns seen in pharmacogenomics data in the context of tailored treatment and medication development. This includes developing medications, predicting their efficacy, introducing medical devices, and implementing treatment plans through the use of algorithms utilizing machine learning, deep learning, and related technologies. With the ability to test life-saving medications, offer knowledge in advance, and target the community-level impact of pharmacogenomics implications-even at the population level-the combination of big data analytics and artificial intelligence in pharmacogenomics is viewed as a paradigm change in health treatments.

Large-scale, data-driven research is replacing case-based studies in the rapidly expanding field of big data in healthcare, including pharmacogenomics. This strategy could have a direct impact on precision and individualized healthcare, lower treatment costs, and enhance patient outcomes. It is anticipated that the application of AI and big data analytics to pharmacogenomics research would significantly advance personalized medicine and healthcare. Big data analytics has been found to be a revolutionary method in pharmacogenomics research, allowing for the effective administration and examination of the large amount of data produced in this area. However, there are a number of obstacles to overcome before big data analytics may be used in pharmacogenomics research. The availability of adequate pharmacogenomics data for analysis is one of the main obstacles. The limited application of pharmacogenomics in clinical practice makes it challenging to obtain sufficient amounts of data, especially labelled cases and controls. Large training datasets are frequently needed for advanced machine learning models, containing labelled cases and controls, which can provide difficulties in the pharmacogenomics environment where there is a lack of such data. The most effective uses of machine learning and big data analytics in pharmacogenomics necessitate proficiency in the field as well as the methodology, which poses a problem in terms of the specific knowledge and abilities required to use these approaches successfully.

[13].

8. APPLICATIONS OF AI AND BIG DATA IN PHARMACOGENOMICS

Pharmacogenomics has been greatly impacted by AI and machine learning, which present promising answers to the problems brought on by the quickly growing amount of high-throughput data. These technologies make it possible to independently identify and examine patterns in the data, which is particularly useful in clinical settings as it allows for the prediction of the pharmacological characteristics of drug targets. By combining genomics and pharmacokinetics, AI and machine learning techniques are well-suited to drug discovery. This enables big data analytics and the extraction of valuable information from massive biomedical genomic datasets [14].

9. RECENT ADVANCES IN PHARMACOGENOMICS RESEARCH AND TECHNOLOGY

Tools and Genomic technology: New developments in genomic technology have greatly enhanced our knowledge of pharmacogenomics and could revolutionize clinical practice. Drug discovery and tailored therapeutics are being revolutionized by key technologies like genome-wide association studies (GWAS), next-generation sequencing (NGS), and sophisticated bioinformatics tools [15].

10. CHALLENGES AND LIMITATIONS

The inability to obtain enough pharmacogenomic data for model development, the integration of heterogeneous data, the requirement for transparent and explainable models, the absence of standardized evaluation metrics, the need for data security, the difficulty of connecting the drug's various layers, and the requirement for precise predictions are some of the difficulties facing AI-powered pharmacogenomics. These difficulties are addressed in a number of forecasts. The goal of explainable AI (XAI) is to create transparency by providing an explanation for the choices made. Leading to the creation of the algorithm. However, achieving interpretability in complex AI models remains a challenge. The integration of AI in healthcare, including pharmacogenomics, raises ethical concerns related to data quality, privacy, bias, and the potential for disparate impact on underrepresented groups. Proactive embedding of ethics in research and implementation processes is advocated to address these concerns and ensure that AI-driven healthcare benefits society while upholding ethical standards. Proactive embedding of ethics in research and implementation processes is advocated to address these concerns and ensure that AI-driven healthcare benefits society while upholding ethical standards. Governance models and bias evaluation checklists have been proposed to guide the ethical deployment of AI in healthcare settings. These efforts are essential to foster trust, mitigate potential harms, and ensure the equitable and ethical use of AI in healthcare. evidence that the reaction to more than 60 pharmaceuticals may be influenced by variations in roughly 20 genes. Evidence-based, peer-reviewed guidelines are available from the Clinical Pharmacogenetics Implementation Consortium (CPIC), an initiative funded by the US National Institutes of Health to help clinicians interpret the results of genomic tests and apply them to patient care. Several examples of pharmacogenomic testing implementation have been described, with approaches varying from pre emotively testing everyone with gene panels to testing particular genes before prescribing specific medications. Regardless of the implementation strategy, however, institutions and physicians alike face difficulties in developing the infrastructure necessary to preserve genetic data that may be important for the duration of a patient's life. Only a limited subset of pharmaceuticals has FDA labelling requiring pharmacogenetics testing, and there is scant evidence of the therapeutic value of this technique. There are not many instances where pharmacogenomics affects clinical utility, despite its enormous potential [16].

11. FUTURE DIRECTIONS

The way medications are utilized to treat individual individuals is being revolutionized by new developments in pharmacogenomics and artificial intelligence. By examining the impact of genetic alterations on pharmacological responses, pharmacogenomics enables researchers to forecast a medicine's effectiveness, prescribe dose, and enhance patient safety. AI is being utilized to create medications, forecast their effectiveness, and implement treatment plans and medical equipment. Among the most important new developments in AI and pharmacogenomics are explainable AI platforms, large data and analytics, machine learning and deep learning, and cooperation between AI researchers and medical practitioners, as well as joint research projects. Artificial neural networks that can analyze big information and spot trends in patient outcomes are made using machine learning and deep learning. Pharmacogenomics' application of big data and analytics aids in determining the clinical and genetic variables influencing patient treatment response and biomarker levels [17].

12. CONCLUSION

With the ability to customize medication treatments according to a person's genetic composition, pharmacogenomics is a revolutionary approach to personalized medicine. Pharmacogenomics can greatly enhance patient outcomes, minimize adverse drug reactions, and optimize drug dosing by comprehending how genetic variations impact drug metabolism, efficacy, and toxicity. Future healthcare will be more tailored, efficient, and accurate because to developments in pharmacogenomic research and the incorporation of cutting-edge technology like gene editing, artificial intelligence (AI), and big data analytics. The field of pharmacogenomics has the potential to develop a healthcare system that is safer, more equal, and more effective as it develops. Because personalized medicine takes lifestyle, environmental, and genetic factors into account, it can help address the problems associated with "one size-fits-all" treatments. Pharmacogenomics can lead to a healthcare environment where patients receive the best treatment based on their individual genetic profile, improving the quality of care and overall health outcomes, with continued research, technological advancement, and the creation of clear, supportive policies. The research included in this volume demonstrates how molecular methods, such as multi-locus genotyping, can be used to

find genetic factors that influence interindividual variation in pharmacological effects in several important clinical contexts, such as psychiatry and cancer. Combining various layers of pharmacological data, such as variation in genetic, phenotypic, genotype pharmacodynamics, and pharmacokinetic processes, with data gathered using state-of-the-art statistical and bioinformatic techniques can help explain the predictable sources of interpatient variability in drug effects. This will result in precise therapy if done correctly [18].

13. AUTHOR CONTRIBUTIONS

All authors are contributed equally.

14. FINANCIAL SUPPORT

None

15. DECLARATION COMPETING INTEREST

The authors have no conflicts of interest to declare.

16. ACKNOWLEDGEMENTS

None

17. REFERENCES

1. Rao C. Evaluation of antiulcer activity of *Picrasma quassioides* Bennett aqueous extract in rodents. Vedic Res Int Phytomed. 2013.
2. Gindi S, Mehta T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro antioxidant activity of leaves of *Ageratum conyzoides* in rat. World J Pharm Pharm Sci. 2013;2:636-649.
3. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):485-490.
4. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Adv Clin Med.
5. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025;20-.
6. Dara SR. An overview of the use of natural indicators in acid-base titrations. UPI J Pharm Med Health Sci. 2024;4(2):29-35. doi:10.37022/jpmhs.v4i2.103.
7. Adiki SK, Lahari K, Dey B, Khalf AM, Al-Sharif SM, Diaf SR, et al. Validated UV method development for the simultaneous estimation of rabeprazole sodium and cinitapride in tablets.
8. Rani CHU, Sumalatha G, Rao CB, Varalakshmi TN. Alzheimer's disease: pharmacotherapeutic interventions. Int J Pharm Chem Sci. 2013;2(2).
9. Sarvani V, Elisha RP, Nama S, Pola LM, Rao CB. Process validation: an essential process in pharmaceutical industry. Int J Med Chem Anal. 2013;3(2):49-52.
10. Dey B, Katakam P, Mitra A, Chandu BR. Comparative evaluation of hypoglycemic potentials of *Eucalyptus* spp. leaf extracts and their encapsulations for controlled delivery. J Pharm Drug Deliv Res. 2014;3(2).
11. Schilsky RL. Implementing personalized cancer care. Am Soc Clin Oncol Educ Book. 2023;43:e3-e10.
12. Gupta PD. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift. Indian J Pharm Sci. 2015;77(2):135-141.
13. Budd WT, Meyers G, Dilts JR, O'Hanlon K, Woody JR, Bostwick DG, et al. Next generation sequencing reveals disparate population frequencies among cytochrome P450 genes: clinical pharmacogenomics of the CYP2 family. Int J Comput Biol Drug Des. 2016;9(1-2):54-86. doi:10.1504/IJCBDD.2016.074984.
14. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111(1):16-24. doi:10.1182/blood-2007-04-077412.
15. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
16. Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK. Pharmacogenomics: an evolving clinical tool for precision medicine. Cleve Clin J Med. 2020;87(2):91-99.
17. Leil TA, Kasichayanula S, Boulton DW, LaCreta F. Evaluation of 4β-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e120.
18. Schultze-Mosgau MH, Lasseter KC, Marbury T, Loewen S, Riecke K. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020;60(8):1030-1038. doi:10.1002/jcph.1608.
19. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293. doi:10.1056/NEJMoa044503.
20. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438-445. doi:10.1016/j.jmoldx.2016.01.003.